期刊论文详细信息
Pharmaceutics
Drug Development for Pediatric Populations: Regulatory Aspects
Jochen Zisowsky1  Andreas Krause2 
[1] id="af1-pharmaceutics-02-00364">Actelion Pharmaceuticals Ltd, Clinical Pharmacology, Gewerbestrasse 16, CH-4123 Allschwil, Switzerla
关键词: pediatrics;    children;    pediatric drug development;    pediatric legislation;    health authorities;    regulatory guidelines;    PIP;    clinical studies;    Modeling and Simulation;    PK/PD modeling;   
DOI  :  10.3390/pharmaceutics2040364
来源: mdpi
PDF
【 摘 要 】

Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Specific guidelines and requirements from, in particular, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) form the regulatory framework. This review summarizes the regulatory requirements and strategies for pediatric drug development from an industry perspective. It covers pediatric study planning and conduct, considerations for first dose in children, appropriate sampling strategies, and different methods for data generation and analysis to generate knowledge about the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug in children. The role of Modeling and Simulation (M&S) in pediatrics is highlighted—including the regulatory basis—and examples of the use of M&S are illustrated to support pediatric drug development.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.

【 预 览 】
附件列表
Files Size Format View
RO202003190051699ZK.pdf 160KB PDF download
  文献评价指标  
  下载次数:18次 浏览次数:55次